Dubois Lupus Erythematosus and Related Syndromes, 8/e > Rheumatology

Dubois’ Lupus Erythematosus was first published in 1966. For the past forty years, the product has distinguished itself internationally as the go-to reference on lupus and related diseases For rheumatologists and internal medicine practitioners who need a comprehensive clinical reference on systemic lupus erythematosus (SLE) and related disorders, this product delivers a complete arsenal of information on SLE, connective tissue diseases, and the antiphospholipid syndromes. New to This Edition First time published in full color 75% new contributors 10 chapters new to this edition Addition of Michael Weisman, Ronald Van Vollenhoven, Nan Shen, and David Isenberg as Associate editors Online website with supplemental images Key Features Authoritative, comprehensive content that balances basic science with clinical expertise Fundamental images of lupus rashes, graphs, algorithms, and copious drug dosing and differential diagnosis tables Includes a patient s guide with glossary and a compliation of resources for patients and health professionals.

.

Section I: What is Lupus? 1. Definition and classification of Lupus and Lupus-Related Disorders 2. The Epidemiology of Lupus Section II: The Pathogenesis of Lupus 3. The Pathogenesis of SLE 4. Genetics of Human SLE 5. Epigenetics of Lupus 6. The Innate Immune System in SLE 7. Cytokines and Interferons in Lupus 8. The Structure and Derivation of Antibodies and Autoantibodies 9. T Cells 10. Regulatory Cells in SLE 11. Apoptosis, Necrosis, and Autophagy 12. Abnormalities in Immune Complex Clearance and Fcy Receptor Function 13. Neural-Immune Interactions: Principles and Relevance to SLE 14. Complement and SLE 15. Mechanisms of Acute Inflammation and Vascular Injury in SLE 16. Mechanisms of Tissue Damage - Free Radicals and Fibrosis 17. Animal Models of SLE 18. Pathogenic Mechanisms in Lupus Nephritis Section III: Autoantibodies 19. Immune Tolerance Defects in Lupus 20. Autoantibodies 21. Autoantigenesis and Entigen-Based Therapy and Vaccination in SLE Section IV: Clinical Aspects of SLE 22. Overview and Clinical Presentation 23. Pathomechanisms of Cutaneous Lupus Erythematosus 24. Skin Disease in Cutaneous Lupus Erythematosus 25. The Musculoskeletal System and Bone Metabolism 26. Pathogenesis and Treatment of Atherosclerosis in Lupus 27. Cardiopulmonary Disease in SLE 28. Pathogenesis of the Nervous System 29. Clinical Aspects of the Nervous System 30. Psychopathology, Neurodiagnostic Testing, and Imaging 31. Ocular, Aural, and Oral Manifestations 32. Management of Sjögren Syndrome in Patients with SLE 33. Gastrointestinal and Hepatic Manifestations 34. Hematologic and Lymphoid Abnormalities in SLE 35. Clinical and Epidemiologic Features of Lupus Nephritis Section V: The Reproductive System & Hormones 36. Pregnancy in Women with SLE 37. Neonatal Lupus Erythematosus 38. Reproductive and Hormonal Issues in Women with Autoimmune Diseases Section VI: Special Considerations, Subsets of SLE and Lupus-Related Syndromes 39. Drug-Induced Lupus: Etiology, Pathogenesis, and Clinical Aspects 40. SLE in Childhood and Adolescence 41. Mixed Connective Tissue Disease and Undifferentiated Connective Tissue Disease 42. Clinical Aspects of the Antiphospholipid Syndrome Section VII: Assessment of Lupus 43. Clinical Application of Serologic Tests, Serum Protein Abnormalities, and Other Clinical Laboratory Tests in SLE 44. Differential Diagnosis and Disease Associations 45. SLE and Infections 46. Clinical Measures, Metrics and Indices Section VIII: Management of SLE 47. Principles of Therapy, Local Measures, Nonsteroidal Medications 48. Systemic Glucocorticoid Therapy in SLE 49. Antimalarial Medications 50. Immunosuppressive Drug Therapy 51. Specialized Treatment Approaches and Niche Therapies for Lupus Subsets 52. Adjunctive and Preventive Measures 53. Novel Therapies for SLE: Biological Agents Available in Practice Today 54. Critical Issues in Drug Development for SLE 55. Socioeconomic and Disability Aspects Section IX: Outcomes and Future Considerations 56. Investigational Agents and Future Therapy for SLE 57. Mortality in SLE Appendix: Lupus Resource Materials Index